Integration site and clonal expansion in human chronic retroviral infection and gene therapy

Viruses

Volumn 6, Issue 11, 2014, Pages 4140-4164

  Niederer, Heather A ^a   Bangham, Charles R M ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Gammaretroviral vector; Gene therapy; HTLV 1; Integration site

Indexed keywords

GAMMARETROVIRAL VECTOR; GLUCOSE TRANSPORTER; GLUCOSE TRANSPORTER 1; INTEGRASE; RETROVIRUS VECTOR; TAX PROTEIN; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS VECTOR;

CELL POPULATION; CHROMATIN; CLINICAL TRIAL (TOPIC); DNA INTEGRATION; DNA SEQUENCE; DNA TRANSCRIPTION; GENE EXPRESSION; GENE THERAPY; GENOME; HIGH THROUGHPUT SEQUENCING; HOST; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; IMMUNE DEFICIENCY; IMMUNE RESPONSE; LIGATION MEDIATED POLYMERASE CHAIN REACTION; LINEAR AMPLIFICATION MEDIATED POLYMERASE CHAIN REACTION; MALIGNANT TRANSFORMATION; NONHUMAN; PATHOGENESIS; POLYMERASE CHAIN REACTION; PROMOTER REGION; RETROVIRUS INFECTION; REVIEW; SURVIVAL; T LYMPHOCYTE; TRANSGENE; ADVERSE EFFECTS; CELL PROLIFERATION; CHRONIC DISEASE; CLASSIFICATION; GENE VECTOR; GENETIC RECOMBINATION; GENETIC VARIABILITY; GENETICS; GENOTYPE; RETROVIRIDAE; VIROLOGY; VIRUS DNA CELL DNA INTERACTION; VIRUS INFECTION;

HUMAN T-LYMPHOTROPIC VIRUS 1;

CELL PROLIFERATION; CHRONIC DISEASE; GENETIC THERAPY; GENETIC VARIATION; GENETIC VECTORS; GENOTYPE; HUMANS; RECOMBINATION, GENETIC; RETROVIRIDAE; RETROVIRIDAE INFECTIONS; TUMOR VIRUS INFECTIONS; VIRUS INTEGRATION;

EID: 84908688764     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v6114140     Document Type: Review

References (122)

1. Blikstad, V.; Benachenhou, F.; Sperber, G.O.; Blomberg, J. Evolution of human endogenous retroviral sequences: A conceptual account. Cell. Mol. Life Sci. 2008, 65, 3348–3365.
2. Cohen, C.J.; Lock, W.M.; Mager, D.L. Endogenous retroviral LTRs as promoters for human genes: A critical assessment. Gene 2009, 448, 105–114.
3. Hacein-Bey-Abina, S.; Garrigue, A.; Wang, G.P.; Soulier, J.; Lim, A.; Morillon, E.; Clappier, E.; Caccavelli, L.; Delabesse, E.; Beldjord, K. et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J. Clin. Investig. 2008, 118, 3132–3142.
4. Howe, S.J.; Mansour, M.R.; Schwarzwaelder, K.; Bartholomae, C.; Hubank, M.; Kempski, H.; Brugman, M.H.; Pike-Overzet, K.; Chatters, S.J.; de Ridder, D. et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J. Clin. Investig. 2008, 118, 3143–3150.
5. Matsuoka, M.; Jeang, K.-T. Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat. Rev. Cancer 2007, 7, 270–280.
6. Igakura, T.; Stinchcombe, J.C.; Goon, P.K.C.; Taylor, G.P.; Weber, J.N.; Griffiths, G.M.; Tanaka, Y.; Osame, M.; Bangham, C.R.M. Spread of HTLV-I between lymphocytes by virus-induced polarization of the cytoskeleton. Science 2003, 299, 1713–1716.
7. Manel, N.; Kim, F.J.; Kinet, S.; Taylor, N.; Sitbon, M.; Battini, J.-L. The ubiquitous glucose transporter GLUT-1 is a receptor for HTLV. Cell 2003, 115, 449–459.
8. Cook, L.B.; Rowan, A.G.; Melamed, A.; Taylor, G.P.; Bangham, C.R.M. HTLV-1-infected T cells contain a single integrated provirus in natural infection. Blood 2012, 120, 3488–3490.
9. Boxus, M.; Willems, L. Mechanisms of HTLV-1 persistence and transformation. Br. J. Cancer 2009, 101, 1497–1501.
10. Matsuoka, M.; Jeang, K.T. Human T-cell leukemia virus type 1 (HTLV-1) and leukemic transformation: viral infectivity, Tax, HBZ and therapy. Oncogene 2011, 30, 1379–1389.
11. Richardson, J.H.; Edwards, A.J.; Cruickshank, J.K.; Rudge, P.; Dalgleish, A.G. In vivo cellular tropism of human T-cell leukemia virus type 1. J. Virol. 1990, 64, 5682–5687.
12. Ijichi, S.; Ramundo, M.B.; Takahashi, H.; Hall, W.W. In vivo cellular tropism of human T cell leukemia virus type II (HTLV-II). J. Exp. Med. 1992, 176, 293–296.
13. Kannian, P.; Yin, H.; Doueiri, R.; Lairmore, M.D.; Fernandez, S.; Green, P.L. Distinct transformation tropism exhibited by human T lymphotropic virus type 1 (HTLV-1) and HTLV-2 is the result of postinfection T cell clonal expansion. J. Virol. 2012, 86, 3757–3766.
14. Moritoyo, T.; Reinhart, T.A.; Moritoyo, H.; Sato, E.; Izumo, S.; Osame, M.; Haase, A.T. Human T-lymphotropic virus type I-associated myelopathy and tax gene expression in CD4+ T lymphocytes. Ann. Neurol. 1996, 40, 84–90.
15. Hanon, E.; Hall, S.; Taylor, G.P.; Saito, M.; Davis, R.; Tanaka, Y.; Usuku, K.; Osame, M.; Weber, J.N.; Bangham, C.R.M. Abundant Tax protein expression in CD4+ T cells infected with human T-cell lymphotropic virus type I (HTLV-I) is prevented by cytotoxic T lymphocytes. Blood 2000, 95, 1386–1392.
16. Kannagi, M.; Harada, S.; Maruyama, I.; Inoko, H.; Igarashi, H.; Kuwashima, G.; Sato, S.; Morita, M.; Kidokoro, M.; Sugimoto, M. Predominant recognition of human T cell leukemia virus type I (HTLV-I) pX gene products by human CD8+ cytotoxic T cells directed against HTLV-I-infected cells. Int. Immunol. 1991, 3, 761–767.
17. Goon, P.K.C.; Biancardi, A.; Fast, N.; Igakura, T.; Hanon, E.; Mosley, A.J.; Asquith, B.; Gould, K.G.; Marshall, S.; Taylor, G.P. et al. Human T cell lymphotropic virus (HTLV) type-1-specific CD8+ T cells: frequency and immunodominance hierarchy. J. Infect. Dis. 2004, 189, 2294–2298.
18. Satou, Y.; Yasunaga, J.-I.; Yoshida, M.; Matsuoka, M. HTLV-I basic leucine zipper factor gene mRNA supports proliferation of adult T cell leukemia cells. Proc. Natl. Acad. Sci. USA 2006, 103, 720–725.
19. Taniguchi, Y.; Nosaka, K.; Yasunaga, J.-I.; Maeda, M.; Mueller, N.; Okayama, A.; Matsuoka, M. Silencing of human T-cell leukemia virus type I gene transcription by epigenetic mechanisms. Retrovirology 2005, 2, 64.
20. Hilburn, S.; Rowan, A.; Demontis, M.-A.; MacNamara, A.; Asquith, B.; Bangham, C.R.M.; Taylor, G.P. In vivo expression of human T-lymphotropic virus type 1 basic leucine-zipper protein generates specific CD8+ and CD4+ T-lymphocyte responses that correlate with clinical outcome. J. Infect. Dis. 2011, 203, 529–536.
21. Macnamara, A.; Rowan, A.; Hilburn, S.; Kadolsky, U.; Fujiwara, H.; Suemori, K.; Yasukawa, M.; Taylor, G.; Bangham, C.R.M.; Asquith, B. HLA class I binding of HBZ determines outcome in HTLV-1 infection. PLoS Pathog. 2010, 6, e1001117.
22. Qasim, W.; Gaspar, H.B.; Thrasher, A.J. Progress and prospects: Gene therapy for inherited immunodeficiencies. Gene Ther. 2009, 16, 1285–1291.
23. Antoine, C.; Müller, S.; Cant, A.; Cavazzana-Calvo, M.; Veys, P.; Vossen, J.; Fasth, A.; Heilmann, C.; Wulffraat, N.; Seger, R. et al. Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968–99. Lancet 2003, 361, 553–560.
24. Cavazzana-Calvo, M.; Hacein-Bey, S.; de Saint Basile, G.; Gross, F.; Yvon, E.; Nusbaum, P.; Selz, F.; Hue, C.; Certain, S.; Casanova, J.-L. et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000, 288, 669–672.
25. Gaspar, H.B.; Parsley, K.L.; Howe, S.; King, D.; Gilmour, K.C.; Sinclair, J.; Brouns, G.; Schmidt, M.; von Kalle, C.; Barington, T. et al. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 2004, 364, 2181–2187.
26. Maetzig, T.; Galla, M.; Baum, C.; Schambach, A. Gammaretroviral vectors: Biology, technology and application. Viruses 2011, 3, 677–713.
27. Cavazzana-Calvo, M.; Payen, E.; Negre, O.; Wang, G.; Hehir, K.; Fusil, F.; Down, J.; Denaro, M.; Brady, T.; Westerman, K. et al. Transfusion independence and HMGA2 activation after gene therapy of human [bgr]-thalassaemia. Nature 2010, 467, 318–322.
28. Cartier, N.; Hacein-Bey-Abina, S.; Bartholomae, C.C.; Veres, G.; Schmidt, M.; Kutschera, I.; Vidaud, M.; Abel, U.; Dal-Cortivo, L.; Caccavelli, L. et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 2009, 326, 818–823.
29. Aiuti, A.; Biasco, L.; Scaramuzza, S.; Ferrua, F.; Cicalese, M.P.; Baricordi, C.; Dionisio, F.; Calabria, A.; Giannelli, S.; Castiello, M.C. et al. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science 2013, 341, 1233151.
30. Biffi, A.; Montini, E.; Lorioli, L.; Cesani, M.; Fumagalli, F.; Plati, T.; Baldoli, C.; Martino, S.; Calabria, A.; Canale, S. et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science 2013, 341, 1233158.
31. Sakuma, T.; Barry, M.A.; Ikeda, Y. Lentiviral vectors: Basic to translational. Biochem. J. 2012, 443, 603–618.
32. Matreyek, K.A.; Engelman, A. Viral and cellular requirements for the nuclear entry of retroviral preintegration nucleoprotein complexes. Viruses 2013, 5, 2483–2511.
33. Dull, T.; Zufferey, R.; Kelly, M.; Mandel, R.J.; Nguyen, M.; Trono, D.; Naldini, L. A third-generation lentivirus vector with a conditional packaging system. J. Virol 1998, 72, 8463–8471.
34. Mueller, P.R.; Wold, B. In vivo footprinting of a muscle specific enhancer by ligation mediated PCR. Science 1989, 246, 780–786.
35. Schmidt, M.; Schwarzwaelder, K.; Bartholomae, C.; Zaoui, K.; Ball, C.; Pilz, I.; Braun, S.; Glimm, H.; Kalle, C.V. High-resolution insertion-site analysis by linear amplification—Mediated PCR (LAM-PCR). Nat. Methods 2007, 4, 1051–1057.
36. Gabriel, R.; Eckenberg, R.; Paruzynski, A.; Bartholomae, C.C.; Nowrouzi, A.; Arens, A.; Howe, S.J.; Recchia, A.; Cattoglio, C.; Wang, W. et al. Comprehensive genomic access to vector integration in clinical gene therapy. Nat. Med. 2009, 15, 1431–1436.
37. Brugman, M.H.; Suerth, J.D.; Rothe, M.; Suerbaum, S.; Schambach, A.; Modlich, U.; Kustikova, O.; Baum, C. Evaluating a ligation-mediated PCR and pyrosequencing method for the detection of clonal contribution in polyclonal retrovirally transduced samples. Hum. Gene Ther. Methods 2013, 24, 68–79.
38. Paruzynski, A.; Arens, A.; Gabriel, R.; Bartholomae, C.C.; Scholz, S.; Wang, W.; Wolf, S.; Glimm, H.; Schmidt, M.; von Kalle, C. Genome-wide high-throughput integrome analyses by nrLAM-PCR and next-generation sequencing. Nat. Protoc. 2010, 5, 1379–1395.
39. Gillet, N.A.; Malani, N.; Melamed, A.; Gormley, N.; Carter, R.; Bentley, D.; Berry, C.; Bushman, F.D.; Taylor, G.P.; Bangham, C.R.M. The host genomic environment of the provirus determines the abundance of HTLV-1-infected T cell clones. Blood 2011, 117, 3113–3122.
40. Berry, C.C.; Gillet, N.A.; Melamed, A.; Gormley, N.; Bangham, C.R.M.; Bushman, F. Estimating abundances of retroviral insertion sites from DNA fragment length data. Bioinformatics 2012, 28, 755–762.
41. Firouzi, S.; Lopez, Y.; Suzuki, Y.; Nakai, K.; Sugano, S.; Yamochi, T.; Watanabe, T. Development and validation of a new high-throughput method to investigate the clonality of HTLV-1-infected cells based on provirus integration sites. Genome Med. 2014, 6, 46.
42. Brady, T.; Roth, S.L.; Malani, N.; Wang, G.P.; Berry, C.C.; Leboulch, P.; Hacein-Bey-Abina, S.; Cavazzana-Calvo, M.; Papapetrou, E.P.; Sadelain, M. et al. A method to sequence and quantify DNA integration for monitoring outcome in gene therapy. Nucl. Acids Res. 2011, 39, e72.
43. Holman, A.G.; Coffin, J.M. Symmetrical base preferences surrounding HIV-1, avian sarcoma/leukosis virus, and murine leukemia virus integration sites. Proc. Natl. Acad. Sci. USA 2005, 102, 6103–6107.
44. Wu, X.; Li, Y.; Crise, B.; Burgess, S.M.; Munroe, D.J. Weak palindromic consensus sequences are a common feature found at the integration target sites of many retroviruses. J. Virol. 2005, 79, 5211–5214.
45. Fujiwara, T.; Craigie, R. Integration of mini-retroviral DNA: A cell-free reaction for biochemical analysis of retroviral integration. Proc. Natl. Acad. Sci. USA 1989, 86, 3065–3069.
46. Derse, D.; Crise, B.; Li, Y.; Princler, G.; Lum, N.; Stewart, C.; McGrath, C.F.; Hughes, S.H.; Munroe, D.J.; Wu, X. Human T-cell leukemia virus type 1 integration target sites in the human genome: Comparison with those of other retroviruses. J. Virol. 2007, 81, 6731–6741.
47. Meekings, K.N.; Leipzig, J.; Bushman, F.D.; Taylor, G.P.; Bangham, C.R.M. HTLV-1 integration into transcriptionally active genomic regions is associated with proviral expression and with HAM/TSP. PLoS Pathog. 2008, 4, e1000027.
48. Melamed, A.; Witkover, A.D.; Laydon, D.J.; Brown, R.; Ladell, K.; Miners, K.; Rowan, A.G.; Gormley, N.; Price, D.A.; Taylor, G.P. et al. Clonality of HTLV-2 in natural infection. PLoS Pathog. 2014, 10, e1004006.
49. De Ravin, S.S.; Su, L.; Theobald, N.; Choi, U.; Macpherson, J.L.; Poidinger, M.; Symonds, G.; Pond, S.M.; Ferris, A.L.; Hughes, S.H. et al. Enhancers are major targets for murine leukemia virus vector integration. J. Virol. 2014, 88, 4504–4513.
50. LaFave, M.C.; Varshney, G.K.; Gildea, D.E.; Wolfsberg, T.G.; Baxevanis, A.D.; Burgess, S.M. MLV integration site selection is driven by strong enhancers and active promoters. Nucl. Acids Res. 2014, 42, 4257–4269.
51. Wu, X.; Li, Y.; Crise, B.; Burgess, S.M. Transcription start regions in the human genome are favored targets for MLV integration. Science 2003, 300, 1749–1751.
52. Cattoglio, C.; Pellin, D.; Rizzi, E.; Maruggi, G.; Corti, G.; Miselli, F.; Sartori, D.; Guffanti, A.; di Serio, C.; Ambrosi, A. et al. High-definition mapping of retroviral integration sites identifies active regulatory elements in human multipotent hematopoietic progenitors. Blood 2010, 116, 5507–5517.
53. Schröder, A.R.W.; Shinn, P.; Chen, H.; Berry, C.; Ecker, J.R.; Bushman, F. HIV-1 integration in the human genome favors active genes and local hotspots. Cell 2002, 110, 521–529.
54. Mitchell, R.S.; Beitzel, B.F.; Schroder, A.R.W.; Shinn, P.; Chen, H.; Berry, C.C.; Ecker, J.R.; Bushman, F.D. Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS Biol. 2004, 2, e234.
55. Melamed, A.; Laydon, D.J.; Gillet, N.A.; Tanaka, Y.; Taylor, G.P.; Bangham, C.R.M. Genome-wide determinants of proviral targeting, clonal abundance and expression in natural HTLV-1 infection. PLoS Pathogens 2013, 9, e1003271.
56. Cook, L.B.; Melamed, A.; Niederer, H.; Valganon, M.; Laydon, D.; Foroni, L.; Taylor, G.P.; Matsuoka, M.; Bangham, C.R.M. The role of HTLV-1 clonality, proviral structure and genomic integration site in adult T cell leukemia/lymphoma. Blood 2014, 123, 3925–3931.
57. Gillet, N.A.; Cook, L.; Laydon, D.J.; Hlela, C.; Verdonck, K.; Alvarez, C.; Gotuzzo, E.; Clark, D.; Farre, L.; Bittencourt, A. et al. Strongyloidiasis and infective dermatitis alter human T lymphotropic virus-1 clonality in vivo. PLoS Pathog. 2013, 9, e1003263.
58. Niederer, H.A.; Laydon, D.J.; Melamed, A.; Elemans, M.; Asquith, B.; Matsuoka, M.; Bangham, C.R. HTLV-1 proviral integration sites differ between asymptomatic carriers and patients with HAM/TSP. Virol. J. 2014, 11, 172.
59. Ernst, J.; Kheradpour, P.; Mikkelsen, T.S.; Shoresh, N.; Ward, L.D.; Epstein, C.B.; Zhang, X.; Wang, L.; Issner, R.; Coyne, M. et al. Mapping and analysis of chromatin state dynamics in nine human cell types. Nature 2011, 473, 43–49.
60. Brady, T.; Agosto, L.M.; Malani, N.; Berry, C.C.; OʼDoherty, U.; Bushman, F. HIV integration site distributions in resting and activated CD4+ T cells infected in culture. AIDS 2009, 23, 1461–1471.
61. Bartholomae, C.C.; Arens, A.; Balaggan, K.S.; Yanez-Munoz, R.J.; Montini, E.; Howe, S.J.; Paruzynski, A.; Korn, B.; Appelt, J.U.; Macneil, A. et al. Lentiviral vector integration profiles differ in rodent postmitotic tissues. Mol. Ther. 2011, 19, 703–710.
62. Lewinski, M.K.; Yamashita, M.; Emerman, M.; Ciuffi, A.; Marshall, H.; Crawford, G.; Collins, F.; Shinn, P.; Leipzig, J.; Hannenhalli, S. et al. Retroviral DNA integration: Viral and cellular determinants of target-site selection. PLoS Pathog. 2006, 2, e60.
63. Engelman, A.; Cherepanov, P. The lentiviral integrase binding protein LEDGF/p75 and HIV-1 replication. PLoS Pathog. 2008, 4, e1000046.
64. Eidahl, J.O.; Crowe, B.L.; North, J.A.; McKee, C.J.; Shkriabai, N.; Feng, L.; Plumb, M.; Graham, R.L.; Gorelick, R.J.; Hess, S. et al. Structural basis for high-affinity binding of LEDGF PWWP to mononucleosomes. Nucl. Acids Res. 2013, 41, 3924–3936.
65. Van Nuland, R.; van Schaik, F.; Simonis, M.; van Heesch, S.; Cuppen, E.; Boelens, R.; Timmers, H.; van Ingen, H. Nucleosomal DNA binding drives the recognition of H3K36-methylated nucleosomes by the PSIP1-PWWP domain. Epigenetics Chromatin 2013, 6, 12.
66. Kolasinska-Zwierz, P.; Down, T.; Latorre, I.; Liu, T.; Liu, X.S.; Ahringer, J. Differential chromatin marking of introns and expressed exons by H3K36me3. Nat. Genetics 2009, 41, 376–381.
67. Ocwieja, K.E.; Brady, T.L.; Ronen, K.; Huegel, A.; Roth, S.L.; Schaller, T.; James, L.C.; Towers, G.J.; Young, J.A.T.; Chanda, S.K. et al. HIV integration targeting: A pathway involving transportin-3 and the nuclear pore protein RanBP2. PLoS Pathog. 2011, 7, e1001313.
68. Ferris, A.L.; Wu, X.; Hughes, C.M.; Stewart, C.; Smith, S.J.; Milne, T.A.; Wang, G.G.; Shun, M.C.; Allis, C.D.; Engelman, A. et al. Lens epithelium-derived growth factor fusion proteins redirect HIV-1 DNA integration. Proc. Natl. Acad. Sci. USA 2010, 107, 3135–3140.
69. Hare, S.; Shun, M.C.; Gupta, S.S.; Valkov, E.; Engelman, A.; Cherepanov, P. A novel co-crystal structure affords the design of gain-of-function lentiviral integrase mutants in the presence of modified PSIP1/LEDGF/p75. PLoS Pathog. 2009, 5, e1000259.
70. De Rijck, J.; de Kogel, C.; Demeulemeester, J.; Vets, S.; El Ashkar, S.; Malani, N.; Bushman, F.D.; Landuyt, B.; Husson, S.J.; Busschots, K. et al. The BET family of proteins targets moloney murine leukemia virus integration near transcription start sites. Cell. Rep. 2013, 5, 886–894.
71. Gupta, S.S.; Maetzig, T.; Maertens, G.N.; Sharif, A.; Rothe, M.; Weidner-Glunde, M.; Galla, M.; Schambach, A.; Cherepanov, P.; Schulz, T.F. Bromo- and extraterminal domain chromatin regulators serve as cofactors for murine leukemia virus integration. J. Virol. 2013, 87, 12721–12736.
72. Sharma, A.; Larue, R.C.; Plumb, M.R.; Malani, N.; Male, F.; Slaughter, A.; Kessl, J.J.; Shkriabai, N.; Coward, E.; Aiyer, S.S. et al. BET proteins promote efficient murine leukemia virus integration at transcription start sites. Proc. Natl. Acad. Sci. USA 2013, 110, 12036–12041.
73. Kanno, T.; Kanno, Y.; Siegel, R.M.; Jang, M.K.; Lenardo, M.J.; Ozato, K. Selective recognition of acetylated histones by bromodomain proteins visualized in living cells. Mol. Cell. 2004, 13, 33–43.
74. Nakamura, Y.; Umehara, T.; Nakano, K.; Jang, M.K.; Shirouzu, M.; Morita, S.; Uda-Tochio, H.; Hamana, H.; Terada, T.; Adachi, N. et al. Crystal structure of the human BRD2 bromodomain: insights into dimerization and recognition of acetylated histone H4. J. Biol. Chem. 2007, 282, 4193–4201.
75. Hacein-Bey-Abina, S.; von Kalle, C.; Schmidt, M.; McCormack, M.P.; Wulffraat, N.; Leboulch, P.; Lim, A.; Osborne, C.S.; Pawliuk, R.; Morillon, E. et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003, 302, 415–419.
76. Laydon, D.J.; Melamed, A.; Sim, A.; Gillet, N.A.; Sim, K.; Darko, S.; Kroll, J.S.; Douek, D.C.; Price, D.A.; Bangham, C.R.M. et al. Quantification of HTLV-1 clonality and TCR diversity. PLoS Computat. Biol. 2014, 10, e1003646.
77. Bangham, C.R.M. CTL quality and the control of human retroviral infections. Eur. J. Immunol. 2009, 39, 1700–1712.
78. Boztug, K.; Schmidt, M.; Schwarzer, A.; Banerjee, P.P.; Díez, I.A.; Dewey, R.A.; Böhm, M.; Nowrouzi, A.; Ball, C.R.; Glimm, H. et al. Stem-cell gene therapy for the Wiskott-Aldrich syndrome. N. Engl. J. Med. 2010, 363, 1918–1927.
79. Braun, C.J.; Boztug, K.; Paruzynski, A.; Witzel, M.; Schwarzer, A.; Rothe, M.; Modlich, U.; Beier, R.; Gohring, G.; Steinemann, D. et al. Gene therapy for Wiskott-Aldrich syndrome--long-term efficacy and genotoxicity. Sci. Transl. Med. 2014, 6, 227-33.
80. Stein, S.; Ott, M.G.; Schultze-Strasser, S.; Jauch, A.; Burwinkel, B.; Kinner, A.; Schmidt, M.; Kramer, A.; Schwable, J.; Glimm, H. et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat. Med. 2010, 16, 198–204.
81. Hacein-Bey-Abina, S.; Hauer, J.; Lim, A.; Picard, C.; Wang, G.P.; Berry, C.C.; Martinache, C.; Rieux-Laucat, F.; Latour, S.; Belohradsky, B.H. et al. Efficacy of gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 2010, 363, 355–364.
82. Kustikova, O.; Fehse, B.; Modlich, U.; Yang, M.; Düllmann, J.; Kamino, K.; von Neuhoff, N.; Schlegelberger, B.; Li, Z.; Baum, C. Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking. Science 2005, 308, 1171–1174.
83. Mukherjee, S.; Thrasher, A.J. Gene therapy for PIDs: Progress, pitfalls and prospects. Gene 2013, 525, 174–181.
84. Aiuti, A.; Cassani, B.; Andolfi, G.; Mirolo, M.; Biasco, L.; Recchia, A.; Urbinati, F.; Valacca, C.; Scaramuzza, S.; Aker, M. et al. Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy. J. Clin. Investig. 2007, 117, 2233–2240.
85. Van Dooren, S.; Pybus, O.G.; Salemi, M.; Liu, H.-F.; Goubau, P.; Remondegui, C.; Talarmin, A.; Gotuzzo, E.; Alcantara, L.C.J.; Galvão-Castro, B. et al. The low evolutionary rate of human T-cell lymphotropic virus type-1 confirmed by analysis of vertical transmission chains. Mol. Biol. Evol. 2004, 21, 603–611.
86. Gillet, N.A.; Gutiérrez, G.; Rodriguez, S.M.; de Brogniez, A.; Renotte, N.; Alvarez, I.; Trono, K.; Willems, L. Massive depletion of bovine leukemia virus proviral clones located in genomic transcriptionally active sites during primary infection. PLoS Pathog. 2013, 9, e1003687.
87. Florins, A.; de Brogniez, A.; Elemans, M.; Bouzar, A.-B.; François, C.; Reichert, M.; Asquith, B.; Willems, L. Viral expression directs the fate of B cells in bovine leukemia virus-infected sheep. J. Virol. 2012, 86, 621–624.
88. Zhang, L.F.; Huynh, K.D.; Lee, J.T. Perinucleolar targeting of the inactive X during S phase: evidence for a role in the maintenance of silencing. Cell 2007, 129, 693–706.
89. Gaspar, H.B.; Cooray, S.; Gilmour, K.C.; Parsley, K.L.; Zhang, F.; Adams, S.; Bjorkegren, E.; Bayford, J.; Brown, L.; Davies, E.G. et al. Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction. Sci. Transl. Med. 2011, 3, 97-80.
90. Candotti, F.; Shaw, K.L.; Muul, L.; Carbonaro, D.; Sokolic, R.; Choi, C.; Schurman, S.H.; Garabedian, E.; Kesserwan, C.; Jagadeesh, G.J. et al. Gene therapy for adenosine deaminase– deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans. Blood 2012, 120, 3635–3646.
91. Davé, U.P.; Akagi, K.; Tripathi, R.; Cleveland, S.M.; Thompson, M.A.; Yi, M.; Stephens, R.; Downing, J.R.; Jenkins, N.A.; Copeland, N.G. Murine leukemias with retroviral insertions at LMO2 are predictive of the leukemias induced in SCID-X1 patients following retroviral gene therapy. PLoS Genetics 2009, 5, e1000491.
92. Bessis, N.; GarciaCozar, F.J.; Boissier, M.C. Immune responses to gene therapy vectors: influence on vector function and effector mechanisms. Gene Ther. 2004, 11, S10–S17.
93. Lamers, C.H.; Willemsen, R.; van Elzakker, P.; van Steenbergen-Langeveld, S.; Broertjes, M.; Oosterwijk-Wakka, J.; Oosterwijk, E.; Sleijfer, S.; Debets, R.; Gratama, J.W. Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells. Blood 2011, 117, 72–82.
94. Mauro, V.P.; Chappell, S.A. A critical analysis of codon optimization in human therapeutics. Trends Mol. Med. 2014, in press.
95. Sherrill-Mix, S.; Lewinski, M.; Famiglietti, M.; Bosque, A.; Malani, N.; Ocwieja, K.; Berry, C.; Looney, D.; Shan, L.; Agosto, L. et al. HIV latency and integration site placement in five cell-based models. Retrovirology 2013, 10, 90.
96. Dahabieh, M.; Ooms, M.; Brumme, C.; Taylor, J.; Harrigan, P.R.; Simon, V.; Sadowski, I. Direct non-productive HIV-1 infection in a T-cell line is driven by cellular activation state and NFkappaB. Retrovirology 2014, 11, 17.
97. Uren, A.G.; Kool, J.; Berns, A.; van Lohuizen, M. Retroviral insertional mutagenesis: past, present and future. Oncogene 2005, 24, 7656–7672.
98. Ranzani, M.; Annunziato, S.; Adams, D.J.; Montini, E. Cancer gene discovery: Exploiting insertional mutagenesis. Mol. Cancer Res. 2013, 11, 1141–1158.
99. McCormack, M.P.; Young, L.F.; Vasudevan, S.; de Graaf, C.A.; Codrington, R.; Rabbitts, T.H.; Jane, S.M.; Curtis, D.J. The Lmo2 oncogene initiates leukemia in mice by inducing thymocyte self-renewal. Science 2010, 327, 879–883.
100. Ott, M.G.; Schmidt, M.; Schwarzwaelder, K.; Stein, S.; Siler, U.; Koehl, U.; Glimm, H.; Kuhlcke, K.; Schilz, A.; Kunkel, H. et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat. Med. 2006, 12, 401–409.
101. Kang, E.M.; Choi, U.; Theobald, N.; Linton, G.; Long Priel, D.A.; Kuhns, D.; Malech, H.L. Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils. Blood 2010, 115, 783–791.
102. Recchia, A.; Bonini, C.; Magnani, Z.; Urbinati, F.; Sartori, D.; Muraro, S.; Tagliafico, E.; Bondanza, A.; Stanghellini, M.T.; Bernardi, M. et al. Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells. Proc. Natl. Acad. Sci. USA 2006, 103, 1457–1462.
103. Cassani, B.; Montini, E.; Maruggi, G.; Ambrosi, A.; Mirolo, M.; Selleri, S.; Biral, E.; Frugnoli, I.; Hernandez-Trujillo, V.; di Serio, C. et al. Integration of retroviral vectors induces minor changes in the transcriptional activity of T cells from ADA-SCID patients treated with gene therapy. Blood 2009, 114, 3546–3556.
104. Zhang, J.; Markus, J.; Bies, J.; Paul, T.; Wolff, L. Three murine leukemia virus integration regions within 100 kilobases upstream of c-myb are proximal to the 5ʼ regulatory region of the gene through DNA looping. J. Virol. 2012, 86, 10524–10532.
105. Cesana, D.; Sgualdino, J.; Rudilosso, L.; Merella, S.; Naldini, L.; Montini, E. Whole transcriptome characterization of aberrant splicing events induced by lentiviral vector integrations. J. Clin. Investig. 2012, 122, 1667–1676.
106. Moiani, A.; Paleari, Y.; Sartori, D.; Mezzadra, R.; Miccio, A.; Cattoglio, C.; Cocchiarella, F.; Lidonnici, M.R.; Ferrari, G.; Mavilio, F. Lentiviral vector integration in the human genome induces alternative splicing and generates aberrant transcripts. J. Clin. Investig. 2012, 122, 1653–1666.
107. Maldarelli, F.; Wu, X.; Su, L.; Simonetti, F.R.; Shao, W.; Hill, S.; Spindler, J.; Ferris, A.L.; Mellors, J.W.; Kearney, M.F. et al. HIV latency. Specific HIV integration sites are linked to clonal expansion and persistence of infected cells. Science 2014, 345, 179–183.
108. Wagner, T.A.; McLaughlin, S.; Garg, K.; Cheung, C.Y.; Larsen, B.B.; Styrchak, S.; Huang, H.C.; Edlefsen, P.T.; Mullins, J.I.; Frenkel, L.M. Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection. Science 2014, 345, 570–573.
109. Nagel, J.; Gross, B.; Meggendorfer, M.; Preiss, C.; Grez, M.; Brack-Werner, R.; Dietzel, S. Stably integrated and expressed retroviral sequences can influence nuclear location and chromatin condensation of the integration locus. Chromosoma 2012, 121, 353–367.
110. Modlich, U.; Navarro, S.; Zychlinski, D.; Maetzig, T.; Knoess, S.; Brugman, M.H.; Schambach, A.; Charrier, S.; Galy, A.; Thrasher, A.J. et al. Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. Mol. Ther. 2009, 17, 1919–1928.
111. Zychlinski, D.; Schambach, A.; Modlich, U.; Maetzig, T.; Meyer, J.; Grassman, E.; Mishra, A.; Baum, C. Physiological promoters reduce the genotoxic risk of integrating gene vectors. Mol. Ther. 2008, 16, 718–725.
112. Cesana, D.; Ranzani, M.; Volpin, M.; Bartholomae, C.; Duros, C.; Artus, A.; Merella, S.; Benedicenti, F.; Sergi Sergi, L.; Sanvito, F. et al. Uncovering and dissecting the genotoxicity of self-inactivating lentiviral vectors in vivo. Mol. Ther. 2014, 22, 774–785.
113. Thornhill, S.I.; Schambach, A.; Howe, S.J.; Ulaganathan, M.; Grassman, E.; Williams, D.; Schiedlmeier, B.; Sebire, N.J.; Gaspar, H.B.; Kinnon, C. et al. Self-inactivating gammaretroviral vectors for gene therapy of X-linked severe combined immunodeficiency. Mol. Ther. 2008, 16, 590–598.
114. Bangham, C.R.; Cook, L.B.; Melamed, A. HTLV-1 clonality in adult T-cell leukaemia and non-malignant HTLV-1 infection. Semin Cancer Biol. 2014, 26, 89–98.
115. Biffi, A.; Bartolomae, C.C.; Cesana, D.; Cartier, N.; Aubourg, P.; Ranzani, M.; Cesani, M.; Benedicenti, F.; Plati, T.; Rubagotti, E. et al. Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection. Blood 2011, 117, 5332–5339.
116. Cattoglio, C.; Facchini, G.; Sartori, D.; Antonelli, A.; Miccio, A.; Cassani, B.; Schmidt, M.; von Kalle, C.; Howe, S.; Thrasher, A.J. et al. Hot spots of retroviral integration in human CD34+ hematopoietic cells. Blood 2007, 110, 1770–1778.
117. Biasco, L.; Ambrosi, A.; Pellin, D.; Bartholomae, C.; Brigida, I.; Roncarolo, M.G.; di Serio, C.; von Kalle, C.; Schmidt, M.; Aiuti, A. Integration profile of retroviral vector in gene therapy treated patients is cell-specific according to gene expression and chromatin conformation of target cell. EMBO Mol. Med. 2011, 3, 89–101.
118. Kustikova, O.S.; Geiger, H.; Li, Z.; Brugman, M.H.; Chambers, S.M.; Shaw, C.A.; Pike-Overzet, K.; Ridder, D.D.; Staal, F.J.T.; Keudell, G.V. et al. Retroviral vector insertion sites associated with dominant hematopoietic clones mark “stemness” pathways. Blood 2007, 109, 1897–1907.
119. Martins, V.C.; Busch, K.; Juraeva, D.; Blum, C.; Ludwig, C.; Rasche, V.; Lasitschka, F.; Mastitsky, S.E.; Brors, B.; Hielscher, T. et al. Cell competition is a tumour suppressor mechanism in the thymus. Nature 2014, 509, 465–470.
120. Fields, P.A.; Taylor, G.P. “Antivirals” in the treatment of adult T cell leukaemia-lymphoma (ATLL). Curr. Hematol. Malig. Rep. 2012, 7, 267–275.
121. Yonekura, K.; Kanzaki, T.; Gunshin, K.; Kawakami, N.; Takatsuka, Y.; Nakano, N.; Tokunaga, M.; Kubota, A.; Takeuchi, S.; Kanekura, T. et al. Effect of anti-CCR4 monoclonal antibody (mogamulizumab) on adult T-cell leukemia-lymphoma: Cutaneous adverse reactions may predict the prognosis. J. Dermatol. 2014, 41, 239–244.
122. Di, W.L.; Mellerio, J.E.; Bernadis, C.; Harper, J.; Abdul-Wahab, A.; Ghani, S.; Chan, L.; Martinez-Queipo, M.; Hara, H.; McNicol, A.M. et al. Phase I study protocol for ex vivo lentiviral gene therapy for the inherited skin disease, Netherton syndrome. Hum. Gene ther. Clin. Dev. 2014, 24, 182–190.